Atrial Fibrillation Therapy Demonstrates Efficacy and Safety in Phase 2b Clinical Trial
Complete results from our budiodarone (ATI-2042) Phase 2b clinical trial demonstrate both efficacy and safety. With this data, we are seeking a pharmaceutical company partner to fully develop this atrial fibrillation therapy. Press Release. Heart Rhythm Society Presentation.
Learn more
A Growing Clinical Stage Product Pipeline
We are developing a portfolio of novel, oral product candidates aimed at large, chronic markets. We currently have four product candidates in clinical trials, three of which are in Phase 2 development.
Learn more
RetroMetabolic Drug Design
We use proprietary technologies to design structurally unique and patentable molecules that retain the efficacy of proven therapies while eliminating specific adverse side effects associated with these therapies.
Learn more
Jefferies 3rd Annual Healthcare Conference